Cargando…

Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma

INTRODUCTION: In the peri-elimination setting, the positive predictive value of trachomatous inflammation–follicular (TF), the primary marker used to determine need for antibiotics for trachoma, is suboptimal. Here, three non-TF measures are used to compare two regions where TF prevalence exceeds th...

Descripción completa

Detalles Bibliográficos
Autores principales: Butcher, Robert, Handley, Becca, Garae, Mackline, Taoaba, Raebwebwe, Pickering, Harry, Bong, Annie, Sokana, Oliver, Burton, Matthew J, Sepúlveda, Nuno, Cama, Ana, Mesurier, Richard Le, Solomon, Anthony W., Mabey, David, Taleo, Fasihah, Tekeraoi, Rabebe, Roberts, Chrissy h
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113835/
https://www.ncbi.nlm.nih.gov/pubmed/32017971
http://dx.doi.org/10.1016/j.jinf.2020.01.015
_version_ 1783513755887337472
author Butcher, Robert
Handley, Becca
Garae, Mackline
Taoaba, Raebwebwe
Pickering, Harry
Bong, Annie
Sokana, Oliver
Burton, Matthew J
Sepúlveda, Nuno
Cama, Ana
Mesurier, Richard Le
Solomon, Anthony W.
Mabey, David
Taleo, Fasihah
Tekeraoi, Rabebe
Roberts, Chrissy h
author_facet Butcher, Robert
Handley, Becca
Garae, Mackline
Taoaba, Raebwebwe
Pickering, Harry
Bong, Annie
Sokana, Oliver
Burton, Matthew J
Sepúlveda, Nuno
Cama, Ana
Mesurier, Richard Le
Solomon, Anthony W.
Mabey, David
Taleo, Fasihah
Tekeraoi, Rabebe
Roberts, Chrissy h
author_sort Butcher, Robert
collection PubMed
description INTRODUCTION: In the peri-elimination setting, the positive predictive value of trachomatous inflammation–follicular (TF), the primary marker used to determine need for antibiotics for trachoma, is suboptimal. Here, three non-TF measures are used to compare two regions where TF prevalence exceeds the threshold for intervention, but where the Chlamydia trachomatis (Ct) prevalence is different. METHODS: Population prevalence of trachoma was measured in Vanuatu (n = 3470) and Kiribati (n = 2922). Dried blood spots (DBS) and conjunctival photographs were collected from every survey participant, and conjunctival swabs were collected from those aged 1–9 years. Individuals were tested for blood anti-Pgp3 antibodies, Ct DNA at the conjunctiva and severity of conjunctival scarring. RESULTS: The prevalence of TF in 1–9-year-olds was 16.5% in Vanuatu and 38.2% in Tarawa. 7% of people aged ≥1 year in Vanuatu had conjunctival scarring compared to 27% in Tarawa. The prevalence of ocular Ct infection in 1–9-year-olds was 1.5% in Vanuatu and 27.4% in Tarawa. The seroconversion rate amongst 1–9-year-old children in Vanuatu and Tarawa was 0.018 and 0.197 events per child per year, respectively. CONCLUSIONS: Comparing Vanuatu to Tarawa demonstrates several markers that could be used to differentiate the trachoma status of populations in these (and other) locations.
format Online
Article
Text
id pubmed-7113835
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-71138352020-04-06 Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma Butcher, Robert Handley, Becca Garae, Mackline Taoaba, Raebwebwe Pickering, Harry Bong, Annie Sokana, Oliver Burton, Matthew J Sepúlveda, Nuno Cama, Ana Mesurier, Richard Le Solomon, Anthony W. Mabey, David Taleo, Fasihah Tekeraoi, Rabebe Roberts, Chrissy h J Infect Article INTRODUCTION: In the peri-elimination setting, the positive predictive value of trachomatous inflammation–follicular (TF), the primary marker used to determine need for antibiotics for trachoma, is suboptimal. Here, three non-TF measures are used to compare two regions where TF prevalence exceeds the threshold for intervention, but where the Chlamydia trachomatis (Ct) prevalence is different. METHODS: Population prevalence of trachoma was measured in Vanuatu (n = 3470) and Kiribati (n = 2922). Dried blood spots (DBS) and conjunctival photographs were collected from every survey participant, and conjunctival swabs were collected from those aged 1–9 years. Individuals were tested for blood anti-Pgp3 antibodies, Ct DNA at the conjunctiva and severity of conjunctival scarring. RESULTS: The prevalence of TF in 1–9-year-olds was 16.5% in Vanuatu and 38.2% in Tarawa. 7% of people aged ≥1 year in Vanuatu had conjunctival scarring compared to 27% in Tarawa. The prevalence of ocular Ct infection in 1–9-year-olds was 1.5% in Vanuatu and 27.4% in Tarawa. The seroconversion rate amongst 1–9-year-old children in Vanuatu and Tarawa was 0.018 and 0.197 events per child per year, respectively. CONCLUSIONS: Comparing Vanuatu to Tarawa demonstrates several markers that could be used to differentiate the trachoma status of populations in these (and other) locations. W.B. Saunders 2020-04 /pmc/articles/PMC7113835/ /pubmed/32017971 http://dx.doi.org/10.1016/j.jinf.2020.01.015 Text en © 2020 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Butcher, Robert
Handley, Becca
Garae, Mackline
Taoaba, Raebwebwe
Pickering, Harry
Bong, Annie
Sokana, Oliver
Burton, Matthew J
Sepúlveda, Nuno
Cama, Ana
Mesurier, Richard Le
Solomon, Anthony W.
Mabey, David
Taleo, Fasihah
Tekeraoi, Rabebe
Roberts, Chrissy h
Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma
title Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma
title_full Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma
title_fullStr Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma
title_full_unstemmed Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma
title_short Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma
title_sort ocular chlamydia trachomatis infection, anti-pgp3 antibodies and conjunctival scarring in vanuatu and tarawa, kiribati before antibiotic treatment for trachoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113835/
https://www.ncbi.nlm.nih.gov/pubmed/32017971
http://dx.doi.org/10.1016/j.jinf.2020.01.015
work_keys_str_mv AT butcherrobert ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT handleybecca ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT garaemackline ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT taoabaraebwebwe ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT pickeringharry ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT bongannie ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT sokanaoliver ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT burtonmatthewj ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT sepulvedanuno ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT camaana ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT mesurierrichardle ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT solomonanthonyw ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT mabeydavid ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT taleofasihah ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT tekeraoirabebe ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma
AT robertschrissyh ocularchlamydiatrachomatisinfectionantipgp3antibodiesandconjunctivalscarringinvanuatuandtarawakiribatibeforeantibiotictreatmentfortrachoma